Small peptides blocking inhibition of factor Xa and tissue factor-factor VIIa by tissue factor pathway inhibitor (TFPI)

Journal of Biological Chemistry

Volumn 289, Issue 3, 2014, Pages 1732-1741

  Dockal, Michael ^a   Hartmann, Rudolf ^a   Fries, Markus ^a   Thomassen, M Christella L G D ^b   Heinzmann, Alexandra ^b   Ehrlich, Hartmut ^a   Rosing, Jan ^b   Osterkamp, Frank ^c   Polakowski, Thomas ^c   Reineke, Ulrich ^c   Griessner, Andreas ^d   Brandstetter, Hans ^d   Scheiflinger, Friedrich ^a  

^a BAXTER INNOVATIONS GMBH   (Austria)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c Pharmaceuticals GmbH 3B   (Germany)

^d UNIVERSITY OF SALZBURG   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT ACTIVITIES; BINDING MECHANISMS; CONTACT SURFACE; HYDROPHOBIC CHARACTER; KUNITZ-TYPE PROTEASE INHIBITORS; REACTIVE CENTER LOOPS; TISSUE FACTOR PATHWAY INHIBITORS; TISSUE FACTOR-FACTOR VIIA;

AMINO ACIDS; COAGULATION; CRYSTAL STRUCTURE; PEPTIDES;

TISSUE;

APROTININ; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7A; KUNITZ 1; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG; COAGULATING AGENT; LIPOPROTEIN; LIPOPROTEIN-ASSOCIATED COAGULATION INHIBITOR; PEPTIDE;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ANTICOAGULATION; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CRYSTAL STRUCTURE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME CONFORMATION; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME STABILITY; HEMOPHILIA A; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; ANTAGONISTS AND INHIBITORS; BLOOD CLOTTING; CHEMISTRY; DRUG EFFECTS; HEMORRHAGE; METABOLISM; PROTEIN SECONDARY STRUCTURE; PROTEIN TERTIARY STRUCTURE; SYNTHESIS;

BLOOD COAGULATION; COAGULANTS; FACTOR VIIA; FACTOR XA; HEMOPHILIA A; HEMORRHAGE; HUMANS; LIPOPROTEINS; PEPTIDES; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY;

EID: 84892650393     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.533836     Document Type: Article

References (43)

1. Huang, Z. F., Wun, T. C., and Broze, G. J., Jr. (1993) Kinetics of factor Xa inhibition by tissue factor pathway inhibitor. J. Biol. Chem. 268, 26950-26955
2. Hackeng, T. M., Seré, K. M., Tans, G., and Rosing, J. (2006) Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor. Proc. Natl. Acad. Sci. U.S.A. 103, 3106-3111 (Pubitemid 43346432)
3. Broze, G. J., Jr., Warren, L. A., Novotny, W. F., Higuchi, D. A., Girard, J. J., and Miletich, J. P. (1988) The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa. Insight into its possible mechanism of action. Blood 71, 335-343 (Pubitemid 18089519)
4. Girard, T. J., Warren, L. A., Novotny, W. F., Likert, K. M., Brown, S. G., Miletich, J. P., and Broze, G. J., Jr. (1989) Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature 338, 518-520 (Pubitemid 19107996)
5. Wun, T. C., Kretzmer, K. K., Girard, T. J., Miletich, J. P., and Broze, G. J., Jr. (1988) Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains. J. Biol. Chem. 263, 6001-6004
6. Burgering, M. J., Orbons, L. P., van der Doelen, A., Mulders, J., Theunissen, H. J., Grootenhuis, P. D., Bode, W., Huber, R., and Stubbs, M. T. (1997) The second Kunitz domain of human tissue factor pathway inhibitor. Cloning, structure determination and interaction with factor Xa. J. Mol. Biol. 269, 395-407 (Pubitemid 27267761)
7. Mine, S., Yamazaki, T., Miyata, T., Hara, S., and Kato, H. (2002) Structural mechanism for heparin-binding of the third Kunitz domain of human tissue factor pathway inhibitor. Biochemistry 41, 78-85 (Pubitemid 34049383)
8. Higuchi, D. A., Wun, T. C., Likert, K. M., and Broze, G. J., Jr. (1992) The effect of leukocyte elastase on tissue factor pathway inhibitor. Blood 79, 1712-1719
9. Petersen, L. C., Bjørn, S. E., Olsen, O. H., Nordfang, O., Norris, F., and Norris, K. (1996) Inhibitory properties of separate recombinant Kunitztype-protease-inhibitor domains from tissue-factor-pathway inhibitor. Eur. J. Biochem. 235, 310-316 (Pubitemid 26048630)
10. Wesselschmidt, R., Likert, K., Girard, T., Wun, T. C., and Broze, G. J., Jr. (1992) Tissue factor pathway inhibitor. The carboxy-terminus is required for optimal inhibition of factor Xa. Blood 79, 2004-2010
11. Lindhout, T., Willems, G., Blezer, R., and Hemker, H. C. (1994) Kinetics of the inhibition of human factor Xa by full-length and truncated recombinant tissue factor pathway inhibitor. Biochem. J. 297, 131-136 (Pubitemid 24025614)
12. Peraramelli, S., Suylen, D. P., Rosing, J., and Hackeng, T. M. (2012) The Kunitz 1 and Kunitz 3 domains of tissue factor pathway inhibitor are required for efficient inhibition of factor Xa. Thromb. Haemost. 108, 266-276
13. Ndonwi, M., Tuley, E. A., and Broze, G. J., Jr. (2010) The Kunitz-3 domain of TFPI-α is required for protein S-dependent enhancement of factor Xa inhibition. Blood 116, 1344-1351
14. Valentin, S., Nordfang, O., Bregengård, C., and Wildgoose, P. (1993) Evidence that the C-terminus of tissue factor pathway inhibitor (TFPI) is essential for its in vitro and in vivo interaction with lipoproteins. Blood Coagul. Fibrinolysis 4, 713-720 (Pubitemid 23343394)
15. Ndonwi, M., and Broze, G., Jr. (2008) Protein S enhances the tissue factor pathway inhibitor inhibition of factor Xa but not its inhibition of factor VIIa-tissue factor. J. Thromb. Haemost. 6, 1044-1046 (Pubitemid 351689932)
16. Ariëns, R. A., Alberio, G., Moia, M., and Mannucci, P. M. (1999) Low levels of heparin-releasable tissue factor pathway inhibitor in young patients with thrombosis. Thromb. Haemost. 81, 203-207 (Pubitemid 29078303)
17. Dahm, A., Van Hylckama Vlieg, A., Bendz, B., Rosendaal, F., Bertina, R. M., and Sandset, P. M. (2003) Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. Blood 101, 4387-4392 (Pubitemid 36857803)
18. Duckers, C., Simioni, P., Spiezia, L., Radu, C., Gavasso, S., Rosing, J., and Castoldi, E. (2008) Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency. Blood 112, 3615-3623
19. Erhardtsen, E., Ezban, M., Madsen, M. T., Diness, V., Glazer, S., Hedner, U., and Nordfang, O. (1995) Blocking of tissue factor pathway inhibitor (TFPI) shortens the bleeding time in rabbits with antibody induced haemophilia A. Blood Coagul. Fibrinolysis 6, 388-394
20. Waters, E. K., Genga, R. M., Schwartz, M. C., Nelson, J. A., Schaub, R. G., Olson, K. A., Kurz, J. C., and McGinness, K. E. (2011) Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor. Blood 117, 5514-5522
21. Liu, T., Scallan, C. D., Broze, G. J., Jr., Patarroyo-White, S., Pierce, G. F., and Johnson, K. W. (2006) Improved coagulation in bleeding disorders by non-anticoagulant sulfated polysaccharides (NASP). Thromb. Haemost. 95, 68-76
22. Prasad, S., Lillicrap, D., Labelle, A., Knappe, S., Keller, T., Burnett, E., Powell, S., and Johnson, K. W. (2008) Efficacy and safety of a new-class hemostatic drug candidate, AV513, in dogs with hemophilia A. Blood 111, 672-679
23. Hedner, U., and Ezban, M. (2008) Tissue factor and factor VIIa as therapeutic targets in disorders of hemostasis. Annu. Rev. Med. 59, 29-41 (Pubitemid 351287922)
24. Zhang, Z., Till, S., Jiang, C., Knappe, S., Reutterer, S., Scheiflinger, F., Szabo, C. M., and Dockal, M. (2013) Structure-activity relationship of the pro- and anticoagulant effects of Fucus vesiculosus fucoidan. Thromb. Haemost. 10.1160/TH13-08-0635
25. Waters, E. K., Genga, R. M., Thomson, H. A., Kurz, J. C., Schaub, R. G., Scheiflinger, F., and McGinness, K. E. (2013) Aptamer BAX 499 mediates inhibition of tissue factor pathway inhibitor via interaction with multiple domains of the protein. J. Thromb. Haemost. 11, 1137-1145
26. Hilden, I., Lauritzen, B., Sørensen, B. B., Clausen, J. T., Jespersgaard, C., Krogh, B. O., Bowler, A. N., Breinholt, J., Gruhler, A., Svensson, L. A., Petersen, H. H., Petersen, L. C., Balling, K. W., Hansen, L., Hermit, M. B., Egebjerg, T., Friederichsen, B., Ezban, M., and Bjørn, S. E. (2012) Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model. Blood 119, 5871-5878
27. Jesty, J., and Esnouf, M. P. (1973) The preparation of activated factorXand its action on prothrombin. Biochem. J. 131, 791-799
28. Seré, K. M., Rosing, J., and Hackeng, T. M. (2004) Inhibition of thrombin generation by protein S at low procoagulant stimuli. Implications for maintenance of the hemostatic balance. Blood 104, 3624-3630 (Pubitemid 39564437)
29. Girard, T. J., and Broze, G. J., Jr. (1993) Tissue factor pathway inhibitor. Methods Enzymol. 222, 195-209 (Pubitemid 23303235)
30. Chan, W. C., and White, P. D. (2000) Fmoc Solid Phase Peptide Synthesis. A Practical Approach, Oxford University Press, New York
31. Evans, P. (2006) Scaling and assessment of data quality. Acta Crystallogr.D Biol. Crystallogr. 62, 72-82
32. Leslie, A. G. (2006) The integration of macromolecular diffraction data. Acta Crystallogr. D Biol. Crystallogr. 62, 48-57
33. McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., and Read, R. J. (2007) Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674 (Pubitemid 47080256)
34. Andrejasic, M., Praaenikar, J., and Turk, D. (2008) PURY: a database of geometric restraints of hetero compounds for refinement in complexes with macromolecular structures. Acta Crystallogr. D Biol. Crystallogr. 64, 1093-1109
35. Brunger, A. T. (2007) Version 1.2 of the Crystallography andNMRsystem. Nat. Protoc. 2, 2728-2733
36. Emsley, P., Lohkamp, B., Scott, W. G., and Cowtan, K. (2010) Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486-501
37. Murshudov, G. N., Vagin, A. A., and Dodson, E. J. (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53, 240-255 (Pubitemid 27235885)
38. Hemker, H. C., Giesen, P., Al Dieri, R., Regnault, V., de Smedt, E., Wagenvoord, R., Lecompte, T., and Béguin, S. (2003) Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol. Haemost. Thromb. 33, 4-15 (Pubitemid 37449290)
39. Knappe, S., Gorczyca, M. E., Jilma, B., Derhaschnig, U., Hartmann, R., Palige, M., Scheiflinger, F., and Dockal, M. (2013) Plasmatic tissue factor pathway inhibitor is a major determinant of clotting in factor VIII inhibited plasma or blood. Thromb. Haemost. 109, 450-457
40. Sichler, K., Hopfner, K. P., Kopetzki, E., Huber, R., Bode, W., and Brandstetter, H. (2002) The influence of residue 190 in the S1 site of trypsin-like serine proteases on substrate selectivity is universally conserved. FEBS Lett. 530, 220-224 (Pubitemid 35248215)
41. Morrison, J. F., and Walsh, C. T. (1988) The behavior and significance of slow-binding enzyme inhibitors. Adv. Enzymol. Relat. Areas Mol. Biol. 61, 201-301
42. Zögg, T., and Brandstetter, H. (2011) Complex assemblies of factors IX and X regulate the initiation, maintenance, and shutdown of blood coagulation. Prog. Mol. Biol. Transl. Sci. 99, 51-103
43. Palige, M., Redl, C., Knappe, S., Ehrlich, H. J., Dockal, M., and Scheiflinger, F. (2010) Procoagulant activity of Laminaria japonica derived fucoidan (BAX513) depends on the interaction with the C-terminus of tissue factor pathway inhibitor. Blood (ASH Annual Meeting Abstracts) 116, Abstr. 4417